Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With Asthma and Allergic Bronchopulmonary Aspergillosis

Next Previous
Trial Profile

Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With Asthma and Allergic Bronchopulmonary Aspergillosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Allergic bronchopulmonary aspergillosis; Asthma
  • Focus Adverse reactions; Proof of concept; Registrational
  • Sponsors Pulmatrix

Most Recent Events

  • 08 Nov 2024 According to a Pulmatrix media release, Research and development expenses decreased approximately $3.2 million to $0.8 million for the three months ended September 30, 2024, the decrease was primarily due to less cost incurred on the PUR1900 program, for which the winding down of the Phase 2b clinical trial was completed during the three months ended September 30, 2024.
  • 27 Jun 2024 This trial has been discontinued in France, according to European Clinical Trials Database record.
  • 28 Mar 2024 According to a Pulmatrix media release, On January 8, 2024, in agreement with its partner Cipla, Pulmatrix announced plans to stop patient enrollment at 8 subjects and company expects to complete all Phase 2b activities by the third quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top